Table 1 |
||
|
Baseline demographics and clinical characteristics |
||
| Characteristic |
Clodronate (n = 530) |
Placebo (n = 539) |
|
|
||
| Mean age ± SD (years) |
52.8 ± 10.6 |
52.7 ± 10.5 |
| Mean BMI ± SD (kg/m2) |
25.8 ± 4.5 |
25.8 ± 4.8 |
| Menopausal status (n) |
||
| Premenopausal |
265 (50%) |
265 (49%) |
| Postmenopausal |
265 (50%) |
274 (51%) |
| Axillary lymph node involvement (n) |
196 (37%) |
202 (38%) |
| Tumor stage (n) |
||
| I |
137 (26%) |
143 (26%) |
| II |
304 (57%) |
305 (57%) |
| III |
48 (9%) |
52 (10%) |
| Unclassifiable |
40 (8%) |
39 (7%) |
| Missing |
1 (0.2%) |
0 (0%) |
| Hormone receptor status (n) |
||
| Oestrogen receptor-positive |
245 (46%) |
240 (45%) |
| Oestrogen receptor-negative |
136 (26%) |
136 (25%) |
| Oestrogen receptor-unknown |
149 (28%) |
163 (30%) |
| Progesterone receptor-positive |
112 (21%) |
116 (22%) |
| Progesterone receptor-negative |
79 (15%) |
75 (14%) |
| Progesterone receptor-unknown |
339 (64%) |
348 (65%) |
|
|
||
|
BMI, body mass index; SD, standard deviation. |
||
|
Powles et al. Breast Cancer Research 2006 8:R13 doi:10.1186/bcr1384 |
||
